The Global Chemosynthetic Polypeptide Drugs Market size is set to reach USD 2.9 billion by 2028, at a CAGR of 5.8%. The growth is attributed to the rising demand for advanced medications and increasing incidence rates of bacterial infections worldwide, coupled with the availability of strong pipeline products which are expected to be approved over the forecast period.
A Chemosynthetic Polypeptide Drug is a type of pharmaceutical that works to slow the progression of chronic conditions and reduce symptoms. Chemosynthetic polypeptides are typically used to treat various forms of cancer, as well as autoimmune disorders such as rheumatoid arthritis or lupus. Chemosynthetic polypeptide drugs are biological medications that are synthetic versions of natural substances produced by living organisms that can be used for therapeutic purposes to mimic the effects of a natural hormone or other protein in the human body.
On the basis of Type, the market is segmented into vasopressin, bacitracin, icatibant, colistin (polymyxin E), and polymyxin B and Colistin Methanesulfonate.
Vasopressin is a naturally occurring hormone that regulates the body's water balance. It also increases blood pressure and lowers heart rate by narrowing or tightening blood vessels, especially in skeletal muscles. Vasopressin may be used to treat low-blood volume caused by bleeding, liver disease, kidney disorders, cancer treatment such as chemotherapy, or surgery when other treatments are not effective. The vasopressins segment is further classified into adrenaline-containing ones such as dopamine or dobutamine and non-adrenaline containing ones like oxytocics including terlipressin and isoproterenol.
Bacitracin is an antibiotic that belongs to the group of polypeptide antibiotics. It falls under the category of narrow-spectrum agents, which means it only attacks a specific type or range of bacteria. Bacitracin can't attack other types such as Gram-positive and Gram-negative organisms. The drug was first isolated from a strain of Streptomyces griseus in 1948 by Dr. Florence. The drug has been used for decades because it's effective against certain kinds of infections.
Icatibant is a synthetic peptide designed to mimic the activity of natural endothelin-A receptor antagonists, acting locally on endothelial cells. It acts as an agonist with respect to vasoconstriction and as a potent inhibitor of nitric oxide production by vascular endothelium. Icatibant also causes increased expression of cellular adhesion molecules such as P-selectin and intercellular cell adhesion molecule-I. It has been investigated for use in treating acute atrial fibrillation.
Colistin is an antibiotic that's used to treat serious bacterial infections. It belongs to a group of antibiotics called polymyxins or colistin, which includes Colistimethate Sodium and Polymyxin B. This drug can be given by mouth in tablet form, intravenously, or through the skin with dressings. Colistin also comes as a powder for injection into a muscle, but this route may only work if kidney function remains intact. The most common side effects are nausea and vomiting, diarrhea, rash, pain at the site where injected.
Polymyxin B is a polypeptide antibiotic that belongs to the group of antibiotics known as colistins. It can be found in some types of bacteriostatic water for injection, but it's also available separately under brand names like Polywax and Fungizone. Its use is limited due to its potential side effects.
Colistin is a last-resort antibiotic used to treat serious infections that do not respond to other treatments. Colistin methanesulfonate has the same mode of action as colistin sulfate, but it can be taken in smaller doses and may have fewer side effects than colistin sulfate.
On the basis of Application, the market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online sales. The respective share of application in the total market is estimated to be 24.0% for hospital pharmacy, 18.0% for retail pharmacy, 34.0% for a drug store, and 30.0% for online sale by 2028.
Hospital pharmacies are used to administer chemotherapeutical drugs in the form of injections, tablets, or liquid. Hospital pharmacies also provide antidotes for drug overdose and poisoning. The use of hospital pharmacy can be seen as a service that both providers to patients with chronic illness and their caregivers As such, they offer advice on medication levels, symptoms management, travel health risks, and general fitness activities like exercise programs which may help people manage their illnesses better. Patients who have undergone chemotherapy will only require medical attention during the period when they are undergoing treatment.
Retail pharmacies are used as a distribution channel for chemosynthetic polypeptide drugs to patients in both hospitals and the community. Chemosynthetic polypeptide drugs that retail pharmacists can provide include bacitracin, colistin methanesulfonate, icatibant, leucovorin calcium oral solution, metronidazole injection, and vitamin K prophylaxis.
Drug stores are one of the major distribution channels for chemosynthetic polypeptide drugs. Chemists in drugstores dispense and sell medicines to customers. Pharmacists as well play a key role here by providing customized advice on treatment based on individual customer's needs, prescription verification with doctors and other pharmacists, as well as discussing side effects and contraindications related to specific medications or groups of medications that have been prescribed or recommended.
Online sale is a growing trend in the market and it has been dominating the pharmaceutical industry as well. Online pharmacies are now competing with traditional retail pharmacies through online advertising, promotion of discounts, etcetera which forces retailers to reduce their prices for prescription drugs. The growth of this industry can be attributed to factors such as easy availability of medicines without traveling long distances or waiting in line at local chemists/pharmacies, ability to carry out searches at any time from anywhere across different types of media.
On the basis of Region, the market is segmented into North America, Europe, Asia Pacific, and Latin America. The North American market North America is expected to dominate the market as a result of its high prevalence rates and widespread adoption. It is expected to account for a market share of over 50%. This region also has favorable government reimbursement policies that promote the use of new drugs by patients and healthcare providers. The pharmaceutical industry in this region is booming owing to high investment opportunities.
Europe leads innovation as well as patent filings which have helped it maintain its position despite economic challenges. This region may be affected by Brexit, making trade tariffs more expensive and difficult post-Brexit. As per the Asia Pacific, there are many economies such as China that offer a low-cost manufacturing base with strong growth prospects; hence attracting drug companies from all over the world including Europe and North American regions. Latin America on the other hand possesses significant potential due to the high disease burden, population, and a rapidly increasing middle class.
Up Market Research published a new report titled “Chemosynthetic Polypeptide Drugs Market research report which is segmented by Types (Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate), By Applications (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales), By Players/Companies Peptides International, Biovectra, X-Gen Pharmaceuticals, Eli Lilly, F.Hoffmann-La Roche, Amylin Pharmaceuticals, Novo-Nordisk, Amgen, Ipsen”.
|Report Attributes||Report Details|
|Report Title||Chemosynthetic Polypeptide Drugs Market Research Report|
|By Type||Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate|
|By Application||Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales|
|By Companies||Peptides International, Biovectra, X-Gen Pharmaceuticals, Eli Lilly, F.Hoffmann-La Roche, Amylin Pharmaceuticals, Novo-Nordisk, Amgen, Ipsen|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||224|
|Number of Tables & Figures||157|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate and By Application Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales.
Some of the companies that are profiled in this report are:
Chemosynthetic Polypeptide Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Chemosynthetic Polypeptide Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Chemosynthetic Polypeptide Drugs Market Report:
Some other reports from this category!